Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

FRESENIUS SE & CO. KGAA

(FRE)
  Report
Real-time Estimate Tradegate  -  03:59 2022-11-30 pm EST
26.80 EUR   +2.00%
12:29aEMEA Morning Briefing: Stocks to Rise as China Covid Policy, Powell Speech in Focus
DJ
11/29FRESENIUS SE : Barclays reiterates its Buy rating
MD
11/29FMC FRESENIUS MEDICAL CARE AG & CO KGAA : Berenberg gives a Buy rating
MD
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Days
:
Hours
:
Minutes
:
Seconds

Europe's generic drugmakers say they may cut output due to energy bills

09/28/2022 | 04:05am EST

FRANKFURT, Sept 28 (Reuters) - Europe's drugmakers have warned they may stop making some cheap generic medicines because of surging electricity costs and are calling for an overhaul of the way they are priced, the latest industry to seek help as the energy crisis deepens.

The generic drug industry lobby group Medicines for Europe, which represents companies including Teva, Novartis's Sandoz unit and Fresenius SE's Kabi business, on Tuesday sent an open letter to European Union member states' energy and health ministers.

The bloc's 27 energy ministers are meeting on Friday to seek agreement on measures to ease the energy crunch in Europe, with a levy on windfall profits of fossil fuel companies and a gas price cap on the table.

A spokesperson for the EU's Czech presidency - responsible for preparing and chairing the meeting - confirmed the receipt of the letter but said the Friday talks were meant to approve proposals by the bloc's executive European Commission.

These have so far not included solutions aimed at drugmakers specifically.

The letter was also addressed to the Commission, which said it would reply "in due course".

Electricity prices have risen ten-fold for some drug factories in Europe and raw material costs have risen by between 50% and 160%, according to the letter.

Its authors asked for the pharmaceutical industry to be exempted from EU moves to reduce electricity consumption, and for off-patent medicines sector to be involved in relaxed state aid rules meant to support the economy.

Generics associations in member states are also petitioning national heath authorities for more flexibility on drug prices, said Medicines for Europe.

"We may discontinue maybe three, maybe five products due to the direct and indirect impact of increasing energy costs," said Elisabeth Stampa, chief executive of Medichem SA, a generic drugs and pharmaceutical ingredients maker based near Barcelona, Spain.

Medicines for Europe's director general Adrian Van Den Hoven told Reuters that higher energy costs were hitting a sector that was forced to consolidate due to price pressure, making the market more vulnerable to supply outages and shortages.

"Higher energy costs just eat all of the margins of many makers of essential medicines in the fixed price system that we operate under in Europe," he said.

The issue centres on the pricing regime. Off-patent medicines are typically sold by low-cost drugmakers at prices set by national health agencies or insurers' associations, which frequently also cut prices.

Generics account for about 70% all dispensed medicines in Europe, many of them to treat serious conditions such as infections or cancer, but make up only 29% of the region's drug bills, according to the lobby group.

The surge in energy costs risks undermining a recent push to boost medicines production in Europe and make the region more self-sufficient after the COVID-19 pandemic exposed a dependence on suppliers abroad and led to a breakdown of certain supply routes.

COVID-lockdown measures in China and the war in Ukraine have made matters worse for logistic and raw material supplies.

Drug supply shortages, which at times disrupt patient care when alternative sources are not available, have a decade-long history in the European off-patent generic drug sector, where pressure on prices by cash-strapped health systems allows only the most cost-efficient suppliers to survive.

While makers of patented innovative drugs are also typically banned from raising prices after a reimbursement rate has been set, the much higher margins keep most of those products profitable.

ENERGY INTENSE

Standard infusions for hospitals are among the most energy intensive drugs to produce because they need to be heated and cooled for sterility. The same goes for the fermentation process behind commonly used antibiotics and therapeutic hormones, said van den Hoven.

Medichem's Stampa said the effects of expensive energy ranged from higher shipping rates to waste disposal contractors charging 30% more.

She declined to name drugs that might be affected as part of an annual review this year, but said customers would be given about six to 12 months to find a new supplier if a product is phased out.

The privately held group made 110 million euros ($106 million) in sales last year with off-patent products such as antibiotic drips, blood thinners and schizophrenia drugs, selling to generic drug companies including Teva and Viatris .

Stampa said indexing drug prices to take production costs into account would be an affordable fix for health bodies in Europe where some off-patent prescription eye drops are reimbursed for less than the price of a pack of gum.

The president of the Italian pharmaceutical industry association, Marcello Cattani, said energy costs are seven times higher than last year, while the U.S. dollar, in which international ingredients are typically paid, is up against the euro.

"The sector cannot pass on higher costs ... The risks of negative impacts on the production and availability of medicines are very high," he said.

($1 = 1.0394 euros) (Additional reporting by Emilio Parodi in Milan and Gabriela Baczynska in Brussels; Editing by Josephine Mason and Mark Potter)


ę Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
FRESENIUS MEDICAL CARE AG & CO. KGAA 0.20% 29.72 Delayed Quote.-48.09%
FRESENIUS SE & CO. KGAA 1.10% 26.56 Delayed Quote.-25.79%
NOVARTIS AG 0.42% 83.65 Delayed Quote.3.76%
UK 10Y CASH -0.01% 3.1655 Delayed Quote.243.73%
VIATRIS INC. -1.34% 11.03 Delayed Quote.-17.37%
All news about FRESENIUS SE & CO. KGAA
12:29aEMEA Morning Briefing: Stocks to Rise as China Covid Policy, Powel..
DJ
11/29FRESENIUS SE : Barclays reiterates its Buy rating
MD
11/29FMC FRESENIUS MEDICAL CARE AG & CO KGAA : Berenberg..
MD
11/28FMC FRESENIUS MEDICAL CARE AG & CO KGAA : UBS remai..
MD
11/28European Midday Briefing: China Protests, Reopeing Doubts Hit I..
DJ
11/28FRESENIUS SE : Raised to Buy by UBS
MD
11/28Fresenius Unit, CSL Vifor Get Regulator's Nod To Market Iron Deficiency Injection In Ch..
MT
11/22German Healthcare Group Fresenius' Investor Elliott Investment Management Reveals Short..
MT
11/22FRESENIUS SE : Barclays reiterates its Buy rating
MD
11/22Fresenius Places Bonds With a Volume of EUR1 Billion
DJ
More news
Analyst Recommendations on FRESENIUS SE & CO. KGAA
More recommendations
Financials
Sales 2022 40 844 M 42 120 M 42 120 M
Net income 2022 1 619 M 1 670 M 1 670 M
Net Debt 2022 23 334 M 24 063 M 24 063 M
P/E ratio 2022 9,08x
Yield 2022 3,07%
Capitalization 14 960 M 15 427 M 15 427 M
EV / Sales 2022 0,94x
EV / Sales 2023 0,86x
Nbr of Employees 319 691
Free-Float 73,0%
Chart FRESENIUS SE & CO. KGAA
Duration : Period :
Fresenius SE & Co. KGaA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FRESENIUS SE & CO. KGAA
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Last Close Price 26,27 €
Average target price 35,83 €
Spread / Average Target 36,4%
EPS Revisions
Managers and Directors
Michael Sen Chief Executive Officer
Sara Hennicken Chief Financial Officer
Wolfgang Kirsch Chairman-Supervisory Board
Michael Albrecht Independent Member-Supervisory Board
Konrad K÷lbl Member-Supervisory Board
Sector and Competitors